CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Association of Cardiovascular Disease With Respiratory Disease The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction AIM2-driven inflammasome activation in heart failure A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Original Research2021 Jun 12;cvab202.

JOURNAL:Cardiovasc Res. Article Link

AIM2-driven inflammasome activation in heart failure

Z Onódi, M Ruppert, D Kucsera et al. Keywords: canakinumab; cardiomyopathy; drug repurposing; heart failure; inflammation; probenecid

Full Text PDF